Patents by Inventor Janet Kao

Janet Kao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6734168
    Abstract: The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: May 11, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Publication number: 20020160957
    Abstract: This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
    Type: Application
    Filed: May 7, 2001
    Publication date: October 31, 2002
    Applicant: The Trustees of Columbia University
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Patent number: 6228837
    Abstract: This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: May 8, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Patent number: 5641867
    Abstract: This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: June 24, 1997
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti